SLC5A2 and type 2 diabetes mellitus: In all studies, significantly more atheroma was present in diabetic mice compared to nondiabetic mice prior to SGLT2 inhibitor treatment; thus, the power to detect a significant reduction in atheroma in T2D mice may be greater.